跨国药企，大消息！股价大涨

Core Viewpoint - Novo Nordisk received positive news as Wegovy was approved by the FDA for the treatment of MASH, providing a new therapeutic option for patients [1][3]. Group 1: Stock Performance - Following the approval news, Novo Nordisk's stock price rebounded, having previously dropped over 20% in the past month [2][8]. - The stock price is currently about one-third of its peak value reached in July 2024 [5][8]. Group 2: Wegovy Approval and Clinical Results - Wegovy is now approved for adults with moderate to severe liver fibrosis associated with MASH, a serious liver condition [3]. - In June 2025, Novo Nordisk plans to present results from the STEP UP 3b clinical trial, showing that higher doses of Wegovy can help obese patients lose an average of 21% of their body weight, with one-third of participants losing 25% or more [3]. Group 3: Financial Performance and Market Challenges - In the first half of 2025, Novo Nordisk reported sales of 154.9 billion Danish Krone (approximately $22.3 billion), an 18% year-over-year increase, with Wegovy accounting for 73% of total revenue [10]. - The company faces significant pressure from illegal generics and increased competition, impacting Wegovy and Ozempic sales [10]. - Novo Nordisk has filed 132 lawsuits against companies selling illegal generics, with some cases resulting in permanent injunctions [10]. Group 4: Strategic Responses - Novo Nordisk is implementing both short-term and long-term strategies to address market challenges, focusing on pipeline development and expanding indications for existing drugs [11].